Drugs Losing Exclusivity in 2029 & Key Intermediates
20 drugs expire in 2029 (public sources), 20 with recorded synthesis routes; key intermediates of 20 drugs are already available through the Unibest supply network. Generic developers typically secure intermediate supply 2–3 years ahead — use this table for shortlisting and RFQ.
| Drug | Tier | Expiry | Indications | Routes | CAS count | Available |
|---|---|---|---|---|---|---|
| Ticagrelor | B · Position early | 2029 | Stroke, Acute coronary syndrome, Myocardial infarction | 5 | 55 | Available ×55 |
| Carfilzomib | B · Position early | 2029 | Multiple myeloma | 3 | 29 | Available ×29 |
| Isavuconazonium Sulfate | C · Watch | 2029 | Mucorales infection, Aspergillus infection, Cryptosporidiosis | 1 | 22 | Available ×22 |
| Cabozantinib S-malate | B · Position early | 2029 | Neuroendocrine tumour, Pancreatic neuroendocrine tumour, Renal cell carcinoma | 3 | 21 | Available ×21 |
| Linagliptin | C · Watch | 2029 | Type 2 diabetes | 4 | 21 | Available ×21 |
| Vonoprazan Acetate | C · Watch | 2029 | Peptic ulcer bleeding | 4 | 20 | Available ×20 |
| Abemaciclib | A · Act now | 2029 | Breast cancer | 2 | 15 | Available ×15 |
| Ribociclib Succinate | A · Act now | 2029 | Breast cancer | 1 | 14 | Available ×14 |
| Dabrafenib Mesylate | B · Position early | 2029 | Thyroid cancer, Colorectal cancer, Glioma | 2 | 12 | Available ×12 |
| Trametinib | C · Watch | 2029 | Thyroid cancer, Glioma, Hairy cell leukaemia | 1 | 13 | Available ×6 |
| Canagliflozin/Metformin Hydrochloride | B · Position early | 2029 | End-stage renal disease, Cardiac and vascular disorders, Abdominal aortic aneurysm | 3 | 19 | Available ×5 |
| Brexpiprazole | A · Act now | 2029 | Schizophrenia, Alzheimer's disease, Agitation | 3 | 12 | Available ×4 |
| Cariprazine Hydrochloride | A · Act now | 2029 | Major depressive disorder, Schizophrenia, Mania | 3 | 21 | Available ×4 |
| Esketamine Hydrochloride | B · Position early | 2029 | Major depressive disorder, Suicidal ideation, Depressive disorder | 8 | 36 | Available ×3 |
| Pimavanserin Tartrate | C · Watch | 2029 | Delusion, Hallucination | 2 | 14 | Available ×3 |
| Delafloxacin | C · Watch | 2029 | Community-acquired bacterial pneumonia, Community-acquired pneumonia, Bacterial skin disease | 2 | 8 | Available ×3 |
| Alpelisib | C · Watch | 2029 | Growth disorder, Genetic disease, PIK3CA-related overgrowth spectrum | 2 | 17 | Available ×2 |
| Mirabegron | B · Position early | 2029 | Neurogenic bladder dysfunction, Overactive bladder | 7 | 36 | Available ×1 |
| Tedizolid Phosphate | C · Watch | 2029 | Skin and skin structure infection, Staphylococcal infection, Bacterial skin disease | 3 | 22 | Available ×1 |
| Cobimetinib Fumarate | C · Watch | 2029 | Melanoma | 3 | 30 | Available ×1 |
Frequently asked questions
Which drugs lose exclusivity in 2029?
20 drugs expire in 2029 per public sources: Abemaciclib, Ribociclib Succinate, Cabozantinib S-malate, Ticagrelor, Canagliflozin/Metformin Hydrochloride, Linagliptin, etc.
When should we start sourcing intermediates for 2029 launches?
Generic developers typically secure development-scale supply 2–3 years before expiry. 20 of the 20 drugs in this table already have on-sale intermediates in the Unibest network; the rest can be RFQ'd per CAS.
Are route and CAS data verified?
All fields are structured data cross-verified from public sources; intermediates carry registry codes and CAS numbers, and every "Available" badge links to real listings.
Source: cross-verified structured fields · Expiry years are public-source estimates; consult individual agencies for authoritative dates · 2026-09-29